Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
US-10576073-B2 · Mar 3, 2020 · US
4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
US10946007B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10946007-B2 |
| Application number | US-202016903579-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 17, 2020 |
| Priority date | Nov 14, 2008 |
| Publication date | Mar 16, 2021 |
| Grant date | Mar 16, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to compounds of formula I: where a, R 1 , and R 3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound of the formula: 2. A process for preparing a compound of the formula: the process comprising contacting a compound of the formula: with a compound of the formula: in the presence of potassium carbonate. 3. The process of claim 2 , wherein the process uses a compound of the formula: 4. The process of claim 2 , wherein the process uses a compound of the formula:
Assignees
Inventors
Classifications
- C07D211/22Primary
by oxygen atoms · CPC title
Drugs for disorders of the cardiovascular system · CPC title
by oxygen atoms · CPC title
Antiepileptics; Anticonvulsants · CPC title
Antiasthmatics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10946007B2 cover?
- The invention relates to compounds of formula I: where a, R 1 , and R 3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process …
- Who is the assignee on this patent?
- Theravance Biopharma R&D Ip Llc
- What technology area does this patent fall under?
- Primary CPC classification C07D211/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).